Active Ingredient(s):Cabozantinib (S)-Malate FDA Approved: * April 25, 2016 Pharm Company: *EXELIXIS INC Category:Cancer
Cabozantinib, sold under the brand names Cometriq and Cabometyx among others, is a medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. It was discovered and developed by Exelixis Inc.
In November 2012, cabozantinib in its capsule formulation was approved by the U.S. Food and Drug Administration (FDA) under the name Cometriq for treating ...
* May have multiple approval dates, manufacturers, or labelers.